// App-Quantinova.ai

2037 : A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Researchers

Presenter

  • Jai N. Patel

Principal Investigators

  • Kouros Owzar

  • Daniel L. Hertz

  • Flora A. Mulkey

  • William K. Kelly

  • Susan Halabi

  • Yoichi Furukawa

  • Cameron Lassiter

  • Susan G. Dorsey

  • Paula N. Friedman

  • Eric J. Small

  • Michael A. Carducci

  • John F. Mahoney

  • Michael J. Kelley

  • Yusuke Nakamura

  • Michiaki Kubo

  • Mark J. Ratain

  • Michael J. Morris

  • Howard L. McLeod

Medical Centers

  • Levine Cancer Institute, Charlotte, SC

  • Alliance Statistical Center, Duke University, Durham, NC

  • University of Michigan College of Pharmacy, Ann Arbor, MI

  • Thomas Jefferson University, Philadelphia, PA

  • The University of Tokyo, Institute of Medical Science, Japan

  • University of Maryland School of Medicine, Baltimore, MD

  • The University of Chicago Medical Center, Chicago, IL

  • University of California, San Francisco, San Francisco, CA

  • Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Durham VA Medical Center/Duke University Medical Center, Durham, NC

  • Riken Center for Integrative Medical Sciences, Japan

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Moffitt Cancer Center, Tampa, FL

Locations

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Peptic ulcer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Prednisone

  • Docetaxel

  • Stribild

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved